Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 5/1/2024

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now


Journal Scan / Research · March 28, 2024

SGLT2 Inhibitors Influence Skeletal Muscle Pathology in Patients With HFrEF

European Journal of Heart Failure




This abstract is available on the publisher's site.

Access this abstract now  

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Heart Failure
Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction
Eur. J. Heart Fail 2024 Mar 11;[EPub Ahead of Print], N Wood, S Straw, CW Cheng, Y Hirata, MG Pereira, H Gallagher, S Egginton, W Ogawa, SB Wheatcroft, KK Witte, LD Roberts, TS Bowen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading